DE69932741D1 - Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen - Google Patents

Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen

Info

Publication number
DE69932741D1
DE69932741D1 DE69932741T DE69932741T DE69932741D1 DE 69932741 D1 DE69932741 D1 DE 69932741D1 DE 69932741 T DE69932741 T DE 69932741T DE 69932741 T DE69932741 T DE 69932741T DE 69932741 D1 DE69932741 D1 DE 69932741D1
Authority
DE
Germany
Prior art keywords
medicament
glycol
derivatives
treatment
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69932741T
Other languages
English (en)
Inventor
Yash Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLUKOR Inc
Original Assignee
GLUKOR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLUKOR Inc filed Critical GLUKOR Inc
Application granted granted Critical
Publication of DE69932741D1 publication Critical patent/DE69932741D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69932741T 1998-12-29 1999-12-29 Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen Expired - Lifetime DE69932741D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11454098P 1998-12-29 1998-12-29
PCT/US1999/031161 WO2000038697A1 (en) 1998-12-29 1999-12-29 Treatment and prevention of hiv and other viral infections

Publications (1)

Publication Number Publication Date
DE69932741D1 true DE69932741D1 (de) 2006-09-21

Family

ID=22355871

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69932741T Expired - Lifetime DE69932741D1 (de) 1998-12-29 1999-12-29 Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen

Country Status (6)

Country Link
EP (1) EP1143981B1 (de)
JP (1) JP2002533400A (de)
AT (1) ATE335494T1 (de)
AU (1) AU2396900A (de)
DE (1) DE69932741D1 (de)
WO (1) WO2000038697A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049672A2 (en) * 2001-10-30 2003-06-19 Microbiotix, Inc. Methods and compositions for treating flavivirus-mediated disease
EP1773363A4 (de) * 2004-07-19 2010-01-27 Life Science Nutrition As Ngna-zusammensetzungen und anwendungsverfahren
US20100119558A1 (en) 2008-11-10 2010-05-13 Scandivir Ab Ngna compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6287598A (ja) * 1985-10-11 1987-04-22 Mect Corp Ｎ−グリコリルノイラミン酸誘導体
JP3930559B2 (ja) * 1994-07-15 2007-06-13 太陽化学株式会社 シアル酸誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
EP1143981B1 (de) 2006-08-09
EP1143981A4 (de) 2003-08-13
EP1143981A1 (de) 2001-10-17
ATE335494T1 (de) 2006-09-15
WO2000038697A1 (en) 2000-07-06
AU2396900A (en) 2000-07-31
JP2002533400A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69815122T2 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
DE3876877T2 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69401577T2 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
DE69610045T2 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ATE229343T1 (de) Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.

Legal Events

Date Code Title Description
8332 No legal effect for de